Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 2/20 | 0.63 |
| ▸ | CTSK | P43235 | 6/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | CTSB | P07858 | 7/20 | 0.55 |
| ▸ | CTSL | P07711 | 6/20 | 0.55 |
| ▸ | CTSS | P25774 | 3/20 | 0.54 |
| ▸ | KYNU | Q16719 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13735151 | 1.00 | CAPN1 (0.63) | CAPN1CTSKALDH1A1ALOX15CTSB | |
| SCHEMBL28551469 | 1.00 | CAPN1 (0.63) | CAPN1CTSKALDH1A1ALOX15CTSB | |
| SCHEMBL30082499 | 1.00 | CAPN1 (0.63) | CAPN1CTSKALDH1A1ALOX15CTSB | |
| SCHEMBL13735150 | 1.00 | CAPN1 (0.63) | CAPN1CTSKALDH1A1ALOX15CTSB | |
| SCHEMBL17959489 | 0.90 | CAPN1 (0.72) | CAPN1CTSKALDH1A1ALOX15CTSB | |
| SCHEMBL17959487 | 0.90 | CAPN1 (0.72) | CAPN1CTSKALDH1A1ALOX15CTSB | |
| SCHEMBL10969199 | 0.90 | CAPN1 (0.72) | CAPN1CTSKALDH1A1ALOX15CTSB | |
| SCHEMBL6831659 | 0.90 | KYNU (0.59) | CAPN1CTSKALDH1A1ALOX15CTSB | |
| SCHEMBL6826924 | 0.90 | KYNU (0.59) | CAPN1CTSKALDH1A1ALOX15CTSB | |
| SCHEMBL1760460 | 0.90 | KYNU (0.59) | CAPN1CTSKALDH1A1ALOX15CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4714953-A1 | MELANOCORTIN 2-TYPE RECEPTOR ANTAGONIST | Scohia Pharma, Inc. (JP) | 2026-03-25 | — | — | EP | disclosed |
| WO-2024237266-A1 | MELANOCORTIN 2-TYPE RECEPTOR ANTAGONIST | 株式会社スコヒアファーマ | 2024-11-21 | — | — | WO | disclosed |
| CN-114040914-B | Quinazolinone derivative, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-115916790-A | Pyrido [2,3-b ] [1,4] oxazines or tetrahydropyrido [2,3-b ] [1,4] oxazepines as IAP antagonists | 百济神州有限公司 | 2023-04-04 | — | — | CN | disclosed |
| US-11407765-B2 | Tetracyclic heteroaryl compounds | ASTRAZENECA, AB (SE) | 2022-08-09 | — | — | US | disclosed |
| CN-114040914-A | Quinazolinone derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2022-02-11 | — | — | CN | disclosed |
| US-20210221823-A1 | TETRACYCLIC HETEROARYL COMPOUNDS | ASTRAZENECA AB (SE) | 2021-07-22 | — | — | US | disclosed |
| US-20210221823-A1 | TETRACYCLIC HETEROARYL COMPOUNDS | ASTRAZENECA AB (SE) | 2021-07-22 | — | — | US | disclosed |
| EP-3790884-A1 | TETRACYCLIC HETEROARYL COMPOUNDS | Astrazeneca AB (SE) | 2021-03-17 | — | — | EP | disclosed |
| US-10597405-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2020-03-24 | — | — | US | disclosed |
| WO-2019215203-A1 | TETRACYCLIC HETEROARYL COMPOUNDS | ASTRAZENECA AB (SE) | 2019-11-14 | — | — | WO | disclosed |
| WO-2019215203-A1 | TETRACYCLIC HETEROARYL COMPOUNDS | ASTRAZENECA AB (SE) | 2019-11-14 | — | — | WO | disclosed |
| US-20190177338-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177338-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, MCL1 | CAPN1 4648/4885CTSK 2917/4885ALDH1A1 26/4885 |
| US-10597405-B2 | Chemical compounds | MKI67, CCNI, MCL1 | CAPN1 4648/4885CTSK 2917/4885ALDH1A1 26/4885 |
| US-20210221823-A1 | TETRACYCLIC HETEROARYL COMPOUNDS | CCNI, MCL1, MKI67 | CAPN1 4703/4885CTSK 1892/4885ALDH1A1 520/4885 |
| US-11407765-B2 | Tetracyclic heteroaryl compounds | CCNI, MCL1, MKI67 | CAPN1 4703/4885CTSK 1892/4885ALDH1A1 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.